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ABSTRACT
The pharmacokinetics and in vitro plasma protein binding of gatifloxacin after a single intramuscular injection 
of 4 mg kg-1 were studied in buffalo calves. The minimum therapeutic concentration of drug was maintained in 
plasma from 1 min to 12 h. Gatifloxacin was rapidly absorbed from the extravascular site of injection, as evident 
from the high value of absorption rate constant (4.91 ± 0.22 h-1) and attained a C
max 
of 2.98 ± 0.08 µg mL-1 at 
1h. The area under the plasma concentration-time curve and apparent volume of distribution were 10.8 ± 0.64 
µg mL-1 h and 3.2 ± 0.08 L kg-1, respectively. Elimination half-life and total body clearance were 7.45 ± 0.55 h 
and 301.5 ± 34.4 mL kg-1h-1, respectively. C
max
/MIC ratio was 14.9 ± 0.3 and systemic bioavailability was 79.7 
± 3.35 per cent. Gatifloxacin was bound to plasma proteins of buffalo calves to the extent of 25.0 ± 1.05 per 
cent. A suitable intramuscular dosage regimen of gatifloxacin in buffalo calves would be 6.0 mg kg-1 followed 
by 5.3 mg kg-1 at 24 h intervals. 
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Introduction
Gatifloxacin, a recently introduced fluoroquinolone, possesses good activity against a 
wide range of gram-positive and gram-negative pathogens, atypical organisms and some 
anaerobes (PERRY et al., 2002). It is commonly indicated for the treatment of acute bacterial 
sinsusitis, chronic bronchitis, pneumonia, urinary tract infections, acute pyelonephritis 
and gonorrhoea (DANIEL, 2001). Fluoroquinolone resistance relates directly to human 
and veterinary usage and emerging bacterial resistance poses the single greatest threat to 
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the future survival of fluoroquinolone drugs as an antibiotic class (BAKKEN, 2004). As 
a member of respiratory quinolones, gatifloxacin possesses enhanced activity against S. 
pneumoniae, H. influenzae and M. catarrhalis (FISH and NORTH, 2001). If a drug is to be 
used effectively, it is important to investigate its pharmacokinetics in each animal species 
and the climate in which the drug is to be used clinically (NAWAZ et al., 1980). Accordingly, 
pharmacokinetic studies of gatifloxacin have been conducted in rabbits (LUTSAR et al., 
1998), mice (ANDES and CRAIG, 2002) and humans (NAKASHIMA et al., 1995). However, 
there is no information available on the pharmacokinetic data of gatifloxacin in buffalo 
species. Keeping in view the marked species variation in the kinetic data of antimicrobial 
drugs, the present study was planned to determine the pharmacokinetics, in vitro plasma 
protein binding and appropriate dosage regimen of gatifloxacin in buffalo calves (Bubalus 
bubalis) after its single intramuscular administration. 
Materials and methods 
The study was conducted on 6 healthy male buffalo calves of non-descript breed 
weighing 90-130 kg and about one year of age. The animals were maintained in the 
departmental animal shed on seasonal green fodder and water ad libitum. Average daytime 
temperature was about 25 °C during the experimental period. Gatifloxacin (Gatiquin, Cipla 
Ltd., Ahmedabad, India) was administered intramuscularly at the dose rate of 4 mg kg-1 
body mass. 
Blood samples (5 mL) were withdrawn from the jugular vein into heparinized glass 
centrifuge tubes before and at 1, 2.5, 5, 10, 15 and 30 min. and at 1, 2, 4, 6, 8, 10, 12, 16 
and 24 h after administration of drug. Plasma was separated by centrifugation at 2000 g 
for 15 min. at room temperature and kept at -20 °C until analysis, which usually took place 
on the day after collection. 
Concentration of gatifloxacin in plasma samples was estimated by a standard 
microbiological assay technique (ARRET et al., 1971) using Escherichia coli (ATCC 
10536) as the test organism. The test organism was cultured on antibiotic medium no. 1 
at 37 °C for 24 h and a suspension was prepared in sterile normal saline. 20 mL of molten 
seed layer containing bacterial suspension was poured on a Petri dish with the help of 
Cornwell Continuous Pipetting Device (Becton Dickinson, New Jersey, USA). Preliminary 
experiments were conducted to determine the actual amount of bacterial suspension to 
be used in the preparation of seed layer. After solidification of the media, six wells were 
punched at equal distances with using a punching device (developed and standardized in 
our laboratory). 
Three alternate wells were filled with one plasma sample and the remaining three wells 
with a standard reference solution of gatifloxacin (0.2 µg mL-1). These assay plates were 
incubated at 34 °C for a period of 12 h. At the end of incubation period the diameters of 
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zone of inhibition of each well was measured with a Fisher Lilly Antibiotic Zone Reader 
(Fisher Scientific Company, New Jersey, USA). Nine replicates were analysed for each 
sample. The repeatability of this method was excellent and within-day error estimation 
was less than 2%. The minimum detection level was 0.05 µg mL-1 of gatifloxacin.
Based on diameter of zone of inhibition of the reference concentrations, the plasma 
levels of gatifloxacin were calculated and expressed as µg mL-1. Pharmacokinetic parameters 
were calculated manually by the least squares regression technique (GIBALDI and PERRIER, 
1982). 
The in vitro plasma protein binding was determined by the equilibrium dialysis 
technique (KUNIN et al., 1959) at plasma concentrations of 0.1, 0.5, 1, 5, 10 and 20 µg mL-
1 of gatifloxacin and the constants for protein binding were obtained (PILLOUD, 1973). 
Results
Table 1. Pharmacokinetic parameters of gatifloxacin in buffalo calves (n = 6) following single 
intramuscular dose of 4 mg kg-1 body mass 
Parameter Unit Mean ± SE
A′ µg mL-1 1.43 ± 0.10
Ka h-1 4.91 ± 0.22
t
˝Ka
h 0.13 ± 0.01
B µg mL-1 1.04 ± 0.03
β h-1 0.09 ± 0.008
t
˝β h 7.45 ± 0.55
AUC µg mL-1.h 10.8 ± 0.64
AUMC µg mL-1.h˛ 122.9 ± 15.2
Vd(area) L kg-1 3.20 ± 0.08
Cl
B
mL kg-1 h-1 301.5 ± 34.4
MRT h 11.0 ± 0.80
td h 32.2 ± 2.4
C
max
µg mL-1 2.98 ± 0.08
t
max
h 1.0 ± 0.00
AUC/MIC ratio 54.3 ± 3.2
Cmax/MIC ratio 14.9 ± 0.30
The mean value for bioavailability (F) was 79.7 ± 3.35%. A′ and B = zero-time plasma drug 
concentration intercepts of the regression lines of absorption and elimination phases, respectively; 
474 Vet. arhiv 76 (6), 471-478, 2006
M. Raipuria et al.: Pharmacokinetics of gatifloxacin in buffalo calves
Ka and β = absorption and elimination rate constants, respectively; t
1⁄2Ka
 = absorption half-life; t
1⁄2β = 
elimination half-life; AUC = area under the plasma concentration-time curve; AUMC = area under 
the first moment curve; Vd(area) = apparent volume of distribution; Cl
B
 = total body clearance; 




 = peak plasma drug 
concentration and time required to attain peak concentration, respectively; MIC = minimum inhibitory 
concentration of drug in plasma. 
Table 2. In vitro binding of gatifloxacin to plasma proteins of buffalo calves. 
Parameter Unit Mean ± SE
β
i
Mol g-1 4.867 × 10-8
Kβ Mol 5.39 × 10
-6
Extent % 25.0 ± 1.05
Each value is the mean of results obtained from three experiments at different plasma concentrations 
ranging from 0.1 to 20 µg mL-1. βi = binding capacity of plasma -proteins with gatifloxacin. Kβ = 
dissociation rate constant of the protein-drug complex.
Mean plasma concentrations of gatifloxacin as a function of time were plotted on a 
semilogarithmic scale (Fig. 1). Following intramuscular administration a mean plasma drug 
concentration of 0.22 ± 0.008 µg mL-1 was detected at 1 min. Peak drug concentration of 
Fig. 1. Semilogarithmic plot of plasma concentration-time profile of gatifloxacin following its 
single intramuscular injection of 4 mg kg-1 in buffalo calves. Values are presented as mean ± SE 
of the results obtained from 6 animals.
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2.98 ± 0.07 µg mL-1 was attained 1h. after injection and was followed by a gradual decline 
to 0.29 ± 0.02 µg mL-1 at 12 h. 
Evaluation of results on observed plasma levels revealed that the disposition of 
gatifloxacin was best fitted to a one-compartment open model and adequately described 
by the exponential equation Cp = Be-βt - A′e-Kat, where Cp is the drug concentration at time 
t, A′ and B are zero-time intercepts of absorption and elimination phases, respectively. 
Ka and β are the absorption and elimination rate constants, respectively, and e represents 
the base of natural logarithm.
Based on the plasma drug levels, various pharmacokinetic parameters pertaining 
to the absorption and elimination of gatifloxacin in buffalo calves were calculated and 
are presented in Table 1. The extent and capacity of in vitro plasma protein binding of 
gatifloxacin are presented in Table 2. 
Discussion
The minimum therapeutic plasma drug concentration was maintained from 1 min. to 12 
h of administration. The MIC
90
 of gatifloxacin against various organisms has been reported 
to be 0.015 to 8 µg mL-1 (ANDES and CRAIG, 2002). However, in view of the influences of 
different factors in vivo, in the present discussion, a concentration of 0.2 µg mL-1 has been 
considered as the MIC of gatifloxacin. Gatifloxacin undergoes minimal hepatic metabolism 
and after single oral doses, up to 88% of the administered drug has been reported to be 
recovered unchanged in urine within 72 h (NAKASHIMA et al., 1995). Due to negligible 
metabolism the chances of any active metabolite being considered as parent compound 
in bioassay is greatly reduced. The early appearance of gatifloxacin in plasma suggested 
rapid absorption of the drug into systemic circulation, which was further confirmed by 
the high values of absorption rate constant (4.91 ± 0.22 h-1). Rapid absorption following 
intramuscular injection has also been reported for another fluoroquinolone: enrofloxacin 
in buffalo bulls (VERMA et al., 1999). The high values of AUC (10.8 ± 0.64 µg mL-1.h) 
and AUMC (122.9 ± 15.2 µg mL-1.h²) of gatifloxacin in buffalo calves indicated that a 
vast area of body fluids and tissues is covered by drug concentration after intramuscular 
injection. High value of AUC has also been reported for gatifloxacin (32.4 mg.h.L-1) after 
oral administration in man (NAKASHIMA et al., 1995) and for the other fluoroquinolones: 
marbofloxacin (15.3 µg mL-1.h) and danofloxacin (10.11 µg mL-1.h) in cattle (THOMAS et 
al., 1994; SHOJAEE, 1997).
The elimination half-life of gatifloxacin in buffalo calves (7.45 ± 0.55 h) was in 
agreement with the findings in human beings, where the half-life of gatifloxacin after oral 
administration was 7-8 h (MIGNOT et al., 2002; NAKASHIMA et al., 1995). However, a low 
value of t
1⁄2β (0.6-1.0 h) has been reported for gatifloxacin in mice (ANDES and CRAIG, 
2002). A short elimination half-life has also been reported for other fluoroquinolones: 
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enrolfloxacin (1.97 h) in buffalo bulls (VERMA et al., 1999) and danofloxacin (4.33 h) in 
cattle (SHOJAEE, 1997). In contrast, ciprofloxacin was found to have a long elimination 
half-life of 10.3 h after intramuscular administration in cattle (SINGH and SRIVASTAVA, 
2000). Total body clearance (Cl
B
) of gatifloxacin in buffalo calves was 301.5 ± 34.4 mL 
kg-1 h-1. Comparable values of Cl
B
 have been reported for gatifloxacin (188-209 mL min-1) 
after oral dose in humans (NAKASHIMA et al, 1995) and enrofloxacin (210.2 mL kg-1h-1) 
after intramuscular dose in buffalo bulls (VERMA et al., 1999). 
C
max
/MIC ratio has been predicted as an effective index to determine the relationship 
between in vivo drug exposure and extent of bacterial killing. A ratio of 8 has been suggested 
as the optimum C
max
/MIC against S. pneumoniae for gatifloxacin (FISH and NORTH, 2001). 
The C
max
/MIC ratio of gatifloxacin was 14.9 ± 0.3 following its intramuscular injection 
in buffalo calves, suggesting much higher plasma levels to produce desired bactericidal 
effects. The systemic bioavailability, which indicates the percentage of drug absorbed 
from the extravascular site of injection to the central compartment, was 79.7 ± 3.35 per 
cent after intramuscular administration of gatifloxacin in buffalo calves. In support of 
the present findings, a high value of bioavailability was reported after an oral dose of 
gatifloxacin (96%) in human (LACRETA et al., 1999) and following intramuscular injection 
of norfloxacin (73%) in cattle (GIPS and SOBACK, 1996). 
Gatifloxacin was bound to the plasma proteins of buffalo calves to the extent of 25.0 
± 1.05 per cent. In confirmation to the present findings, 20% serum binding of gatifloxacin 
has been reported in human beings (NAKASHIMA et al., 1995). Further, the majority of the 
fluoroquinolones have been shown to exhibit low plasma protein binding, predominantly 
to albumin, ranging from 20-40 per cent (BERGOGNE-BEREZIN, 2002). However, from 
the low value of β
i
 it may be inferred that the binding of gatifloxacin to plasma proteins 
is weak in buffalo calves and that it is reversible, as evident from the high value of the 
dissociation rate constant of the protein drug complex. 
Taking a convenient dosage interval of 24 h, the priming and maintenance doses of 
gatifloxacin, to maintain the minimum a therapeutic plasma level of 0.2 µg mL-1, were 
calculated to be 5.97 and 5.33 mg kg-1, respectively. However, under field conditions a 
suitable intramuscular dosage regimen of gatifloxacin in buffalo calves would be 6.0 mg 
kg-1 followed by 5.3 mg kg-1 at 24 h intervals. 
The high values of AUC, Vd(area), t
1⁄2β and Cmax/MIC ratio and moderate bioavailability, 
along with rapid absorption following intramuscular administration of gatifloxacin, 
suggested that gatifloxacin may be effectively employed by intramuscular injection in the 
treatment of bacterial infections in buffalo calves.
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SAŽETAK
Farmakokinetika i in vivo vezanje gatifloksacina na proteine plazme istraživani su u bivolje teladi nakon 
jednokratne intramuskularne primjene u dozi od 4 mg/kg. Minimalna terapijska koncentracija lijeka održavana je 
u plazmi u tijeku od 1 minute do 12 sati. Gatifloksacin se brzo resorbirao s mjesta ubrizgavanja što je vidljivo po 
visokoj vrijednosti konstante brzine apsorpcije (4,91 ± 0,22 sati) i postignute C
max
 2,98 ± 0,08 µg/mL/sat. Površina 
ispod koncentracijske krivulje u plazmi iznosila je 10,8 ± 0,64 µg/mL/sat, a prividni volumen raspodjele 3,2 ± 
0,08 L/kg. Poluvrijeme izlučivanja iznosilo je 7,45 ± 0,55 sati, a ukupni tjelesni klirens 301,5 ± 34,4 mL/kg/sat. 
Omjer C
max
/MIC bio je 14,9 ± 0,3, a sustavna bioraspoloživost iznosila je 79,7 ± 3,35%. Gatifloksacin je bio 
vezan na bjelančevine plazme do 25,0 ± 1,05%. Prikladno intramuskularno doziranje u bivolje teladi bilo bi 6,0 
mg/kg, a u sljedećim dozama treba davati 5,3 mg/kg u razmacima od 24 sata.
Ključne riječi: bivolja telad, doziranje, gatifloksacin, farmakokinetika
